TECX logo

TECTONIC THERAPEUTIC INC

TECXNASDAQ
🏆 #3088 by market capEarnings Nov 5US Equity
$23.28▼ $0.17 (−0.72%)
After hours · at close
🔔
Track TECX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.7%
7d▼ 12.1%
14d▼ 18.2%
30d▼ 34.8%
ytd▲ 11.7%
1y▲ 46.2%
🏦Market Cap
$439M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$22.91 – $23.74
52-Week Range
$14.60 – $39.53
Volume
$2.42B
Avg Volume
$2.80B
Shares Outstanding
18.9M
Next Earnings
Nov 28, 2026

Fundamentals Snapshot

Annual Revenue
$40M
Last Q Revenue
$11M
P/E Ratio
-5.0
P/S Ratio
0.0x
EPS (TTM)
$-4.52
Dividend Yield
0.00%
Dilution (1yr)
+23.9%

Why Investors Own TECX

  • ✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 58% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TECX logo

TECTONIC THERAPEUTIC INC

TECX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$84M▲ +44.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$60M▲ +1.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.3M▲ +23.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$253M▲ +$115M YoY
StockOtter · stockotter.space

About TECTONIC THERAPEUTIC INC

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Ratings

ⓘ
Consensus
Buy
16 analysts
Strong Buy6
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

TECTONIC THERAPEUTIC INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift TECX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

TECTONIC THERAPEUTIC INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.